Postbariatric Hypoglycemia
2
Pipeline Programs
1
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2023
2024
2025
2026
MBX BiosciencesMBX 1416
MBX BiosciencesMBX 1416
Clinical Trials (2)
Total enrollment: 79 patients across 2 trials
Study to Evaluate Efficacy and Dose Response of Imapextide (STEADI)
Start: Aug 2025Est. completion: Jan 202610 patients
Phase 2Recruiting
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of MBX 1416 in Healthy Subjects
Start: Sep 2023Est. completion: Dec 202469 patients
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 79 patients
1 companies competing in this space